Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A response-based dosing strategy for ponatinib (Iclusig) in chronic myeloid leukemia (CML) significantly reduces dangerous arterial side effects. Five-year data from the phase 2 OPTIC trial show that starting at 45 mg and dropping to 15 mg after response is now the FDA-approved approach. The strategy slashed arterial occlusive event risk from up to 35% down to 15%.
Ponatinib (Iclusig) is one of the most potent treatments for chronic-phase CML, especially for patients resistant to at least two prior tyrosine kinase inhibitors (TKIs) or carrying the hard-to-treat BCR::ABL1 T315I mutation. But its early use was clouded by an unexpectedly high risk of arterial occlusive events — affecting 25%–35% of patients. The OPTIC trial set out to find a smarter way to use the drug.
The phase 2 trial tested three starting doses — 45 mg, 30 mg, and 15 mg daily — with patients in the higher-dose arms stepping down to 15 mg once they achieved a meaningful response. The 45 mg starting dose proved most effective, particularly for T315I mutation carriers. Crucially, most patients maintained their response after the dose reduction, and those who lost it largely regained it after re-escalation.
By the Numbers:
Why it matters: This data cemented the 45 mg → 15 mg response-based dosing as the approved label strategy for ponatinib, giving clinicians a clear, evidence-backed way to preserve the drug's potency while meaningfully reducing life-threatening cardiovascular risks.